デフォルト表紙
市場調査レポート
商品コード
1602831

抗真菌薬市場:感染タイプ、剤型、治療適応症別-2025-2030年の世界予測

Antifungal Drugs Market by Infection Type (Superficial Fungal Infection, Systemic Fungal infection), Type (Allylamines, Azoles, Echinocandins), Form, Therapeutic Indications - Global Forecast 2025-2030


出版日
発行
360iResearch
ページ情報
英文 190 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.87円
抗真菌薬市場:感染タイプ、剤型、治療適応症別-2025-2030年の世界予測
出版日: 2024年10月31日
発行: 360iResearch
ページ情報: 英文 190 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗真菌薬市場は、2023年に148億9,000万米ドルと評価され、2024年には158億米ドルに達すると予測され、CAGR 6.19%で成長し、2030年には226億9,000万米ドルに達すると予測されています。

抗真菌薬市場は、人体のさまざまな部位に感染する真菌感染症を治療するために開発された医薬品の幅広いカテゴリーを対象としています。これらの感染症は、皮膚や爪の感染症のような表面的なものから、内臓に影響を及ぼす全身的で生命を脅かす可能性のある疾患まで多岐にわたる。抗真菌薬の必要性は、世界の人口の増加、都市化、AIDSやがんなどの免疫不全状態に拍車をかけ、真菌感染症の発生率が上昇していることが主な要因となっています。抗真菌薬の用途は幅広く、水虫の市販治療から侵襲性アスペルギルス症などの重症感染症の処方薬まで含まれます。主なエンドユーザーには、病院、診療所、在宅介護の現場が含まれ、これらの医薬品の配布や投与に不可欠です。

主な市場の統計
基準年[2023] 148億9,000万米ドル
予測年[2024] 158億米ドル
予測年[2030] 226億9,000万米ドル
CAGR(%) 6.19%

市場の成長は、真菌感染症に対する意識の高まり、薬剤製剤の進歩、研究資金の増加などの要因に影響されます。また、院内感染の増加により、より効果的で即効性のある抗真菌治療に対する需要が高まっています。同市場では、新規薬剤クラスの開拓、薬剤デリバリーシステムの改良、多剤耐性株に対する標的治療などに潜在的なビジネスチャンスがあると見ています。こうした機会を生かすには、研究開発への継続的投資と製薬業界内の戦略的提携が不可欠です。

しかし、薬剤耐性、現在の治療による副作用、薬剤承認に関する厳しい規制方針など、市場の成長には限界があります。さらに、医薬品開発にかかる高いコストと市場開拓に要する膨大な時間が大きな課題となっています。技術革新の最良の分野としては、真菌病原体の耐性メカニズムを理解するためのゲノム研究や、天然由来の抗真菌化合物の探索が挙げられます。市場はダイナミックで競争が激しく、ジェネリック医薬品メーカーとの競争も激しいため、費用対効果の高いソリューションが求められています。最先端の研究や戦略的提携に投資し、抗真菌剤の有効性を高め、副作用を軽減する企業は、この進化する市場環境において有利なポジションを確保することができます。

市場力学:急速に進化する抗真菌薬市場の主要市場インサイトを公開

抗真菌薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

  • 市場促進要因
    • 世界の真菌感染症の流行
    • 無数の真菌感染症に関する高い認識レベル
    • 抗真菌薬に対する政府の好意的な承認
  • 市場抑制要因
    • 従来の抗真菌薬に対する嗜好の継続
  • 市場機会
    • 研究開発資金の増加と製品イノベーションへの注力
    • 抗真菌薬に関する戦略的提携とパートナーシップ
  • 市場の課題
    • 偽造医薬品の存在とブランド医薬品の特許切れ

ポーターのファイブフォース:抗真菌薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析:抗真菌薬市場における外部からの影響の把握

外部マクロ環境要因は、抗真菌薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析抗真菌薬市場における競合情勢の把握

抗真菌薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス抗真菌薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、抗真菌薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨抗真菌薬市場における成功への道筋を描く

抗真菌薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています:

1.市場の浸透度:現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度:新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化:最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報:競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション:将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています:

1.現在の市場規模と今後の成長予測は?

2.最高の投資機会を提供する製品、セグメント、地域はどこか?

3.市場を形成する主な技術動向と規制の影響とは?

4.主要ベンダーの市場シェアと競合ポジションは?

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 世界中で真菌感染症の罹患率が増加
      • さまざまな真菌感染症に関する高い意識レベル
      • 抗真菌薬に対する政府の好意的な承認
    • 抑制要因
      • 従来の抗真菌薬を引き続き優先
    • 機会
      • 研究開発資金の増加と製品イノベーションへの注力
      • 抗真菌薬に関する戦略的提携とパートナーシップ
    • 課題
      • 偽造医薬品の存在とブランド医薬品の特許切れ
  • 市場セグメンテーション分析
  • ポーターのファイブフォース分析
  • PESTEL分析
    • 政治的
    • 経済
    • 社交
    • 技術的
    • 法律上
    • 環境

第6章 抗真菌薬市場感染タイプ別

  • 表面真菌感染症
  • 全身性真菌感染症

第7章 抗真菌薬市場:タイプ別

  • アリルアミン
    • ブテナフィン
    • ナフチフィン
    • テルビナフィン
  • アゾール
    • イミダゾール
    • チアゾール
    • ボリカナゾール
  • エキノキャンディン
    • アニデュラファンギン
    • カスポファンギン
    • ミカファンギン
  • ポリエン
    • アンホテリシンB
    • カンジシジン
    • ハマイシン
    • ナタマイシン

第8章 抗真菌薬市場:形態別

  • 軟膏
  • タブレット

第9章 抗真菌薬市場治療適応症別

  • アスペルギルス症
  • カンジダ症
  • 皮膚糸状菌症

第10章 南北アメリカの抗真菌薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第11章 アジア太平洋地域の抗真菌薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第12章 欧州・中東・アフリカの抗真菌薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第13章 競合情勢

  • 市場シェア分析2023
  • FPNVポジショニングマトリックス, 2023
  • 競合シナリオ分析
  • 戦略分析と提言

企業一覧

  • Abbott Laboratories
  • Astellas Pharma Inc.
  • Bayer HealthCare Pharmaceuticals LLC
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Cadila Pharmaceuticals Limited
  • Cardinal Health, Inc.
  • Cipla, Inc.
  • Enzon Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Hologic, Inc.
  • Johnson & Johnson
  • Lakewood-Amedex, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer, Inc.
  • Quest Diagnostics Incorporated
  • SCYNEXIS, Inc.
  • Sigma-Aldrich, Inc.
  • Sun Pharmaceutical Industries Ltd.
図表

LIST OF FIGURES

  • FIGURE 1. ANTIFUNGAL DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIFUNGAL DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ANTIFUNGAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ANTIFUNGAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIFUNGAL DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIFUNGAL DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY SUPERFICIAL FUNGAL INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY SYSTEMIC FUNGAL INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY BUTENAFINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY NAFTIFINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY TERBINAFINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY IMIDAZOLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY THIAZOLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY VORICANAZOLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ANIDULAFUNGIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CASPOFUNGIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY MICAFUNGIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY AMPHOTERICIN B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CANDICIDIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY HAMYCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY NATAMYCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY POWDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 107. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 112. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 113. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 115. INDIA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 119. INDIA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 120. INDIA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 121. INDIA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 127. INDONESIA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 128. INDONESIA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 129. INDONESIA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 130. INDONESIA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 131. JAPAN ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. JAPAN ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 134. JAPAN ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 135. JAPAN ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 136. JAPAN ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 137. JAPAN ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 138. JAPAN ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 139. MALAYSIA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. MALAYSIA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. MALAYSIA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 142. MALAYSIA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 143. MALAYSIA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 144. MALAYSIA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 145. MALAYSIA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 146. MALAYSIA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. PHILIPPINES ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 150. PHILIPPINES ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 152. PHILIPPINES ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 154. PHILIPPINES ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 155. SINGAPORE ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. SINGAPORE ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. SINGAPORE ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 158. SINGAPORE ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 159. SINGAPORE ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 160. SINGAPORE ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 161. SINGAPORE ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 162. SINGAPORE ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH KOREA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH KOREA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH KOREA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH KOREA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH KOREA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 171. TAIWAN ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. TAIWAN ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. TAIWAN ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 174. TAIWAN ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 175. TAIWAN ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 176. TAIWAN ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 177. TAIWAN ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 178. TAIWAN ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 179. THAILAND ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. THAILAND ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. THAILAND ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 182. THAILAND ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 183. THAILAND ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 184. THAILAND ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 185. THAILAND ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 186. THAILAND ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 187. VIETNAM ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. VIETNAM ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. VIETNAM ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 190. VIETNAM ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 191. VIETNAM ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 192. VIETNAM ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 193. VIETNAM ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 194. VIETNAM ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 204. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 207. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 208. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 209. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 210. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 211. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 212. EGYPT ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. EGYPT ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. EGYPT ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 215. EGYPT ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 216. EGYPT ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 217. EGYPT ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 218. EGYPT ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 219. EGYPT ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 220. FINLAND ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. FINLAND ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. FINLAND ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 223. FINLAND ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 224. FINLAND ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 225. FINLAND ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 226. FINLAND ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 227. FINLAND ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 228. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 231. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 232. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 233. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 234. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 235. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 236. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 239. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 240. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 241. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 242. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 243. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 244. ISRAEL ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. ISRAEL ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. ISRAEL ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 247. ISRAEL ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 248. ISRAEL ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 249. ISRAEL ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 250. ISRAEL ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 251. ISRAEL ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 252. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 255. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 256. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 257. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 258. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 259. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 260. NETHERLANDS ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 262. NETHERLANDS ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 264. NETHERLANDS ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 266. NETHERLANDS ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 268. NIGERIA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. NIGERIA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. NIGERIA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 271. NIGERIA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 272. NIGERIA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 273. NIGERIA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 274. NIGERIA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 275. NIGERIA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 276. NORWAY ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. NORWAY ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. NORWAY ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 279. NORWAY ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 280. NORWAY ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 281. NORWAY ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 282. NORWAY ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 283. NORWAY ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 284. POLAND ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. POLAND ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. POLAND ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 287. POLAND ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 288. POLAND ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 289. POLAND ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 290. POLAND ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 291. POLAND ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 292. QATAR ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 293. QATAR ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 294. QATAR ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 295. QATAR ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 296. QATAR ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 297. QATAR ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 298. QATAR ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 299. QATAR ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 300. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 301. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 302. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 303. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 304. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 305. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 306. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 307. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 308. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 310. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 312. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 314. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 316. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 317. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 318. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 320. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 322. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 324. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 325. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 326. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 327. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 328. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 329. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 330. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 331. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 332. SWEDEN ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 333. SWEDEN ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 334. SWEDEN ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 335. SWEDEN ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 336. SWEDEN ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 337. SWEDEN ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 338. SWEDEN ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 339. SWEDEN ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 340. SWITZERLAND ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 341. SWITZERLAND ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 342. SWITZERLAND ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 343. SWITZERLAND ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 344. SWITZERLAND ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 345. SWITZERLAND ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 346. SWITZERLAND ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 347. SWITZERLAND ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 348. TURKEY ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 349. TURKEY ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 350. TURKEY ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 351. TURKEY ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 352. TURKEY ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 353. TURKEY ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 354. TURKEY ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 355. TURKEY ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 356. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 357. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 358. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 359. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 360. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 361. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 362. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 363. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 364. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 365. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MI
目次
Product Code: MRR-4312A385A460

The Antifungal Drugs Market was valued at USD 14.89 billion in 2023, expected to reach USD 15.80 billion in 2024, and is projected to grow at a CAGR of 6.19%, to USD 22.69 billion by 2030.

The antifungal drugs market is dedicated to the broad category of pharmaceuticals developed to treat fungal infections, which affect various parts of the human body. These infections range from superficial, like skin or nail infections, to systemic and potentially life-threatening diseases affecting internal organs. The necessity for antifungal medications is primarily driven by the rising incidence of fungal infections, spurred by increasing global populations, urbanization, and immunocompromised conditions such as AIDS and cancer. Applications of antifungal drugs are extensive, including over-the-counter treatments for athlete's foot to prescription medications for more severe infections like invasive aspergillosis. Key end-users include hospitals, clinics, and home-care settings, which are crucial to distributing and administering these medications.

KEY MARKET STATISTICS
Base Year [2023] USD 14.89 billion
Estimated Year [2024] USD 15.80 billion
Forecast Year [2030] USD 22.69 billion
CAGR (%) 6.19%

Market growth is influenced by factors such as increased awareness about fungal infections, advancements in drug formulations, and a rise in research funding. Additionally, the incidence of hospital-acquired infections is driving demand for more effective and rapid-acting antifungal treatments. The market sees potential opportunities in the development of novel drug classes, improved drug-delivery systems, and targeted therapies for multidrug-resistant strains. To capitalize on these opportunities, continued investment in R&D and strategic partnerships within the pharmaceutical industry are essential.

However, market growth faces limitations, including drug resistance, adverse side effects of current treatments, and stringent regulatory policies for drug approval. Furthermore, the high cost of drug development and the extensive time required for market introduction present significant challenges. Best areas of innovation include genomic research to understand fungal pathogens' resistance mechanisms and the exploration of naturally derived antifungal compounds. The market is dynamic and competitive, with strong competition from generic drug manufacturers pushing for cost-effective solutions. Businesses that invest in cutting-edge research and strategic collaborations to enhance antifungal efficacy and reduce side effects are poised for advantageous positioning in this evolving market landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antifungal Drugs Market

The Antifungal Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of fungal infection among population worldwide
    • High awareness levels pertaining to myriad fungal infections
    • Favorable government approvals for antifungal drugs
  • Market Restraints
    • Continued preference for conventional antifungal drugs
  • Market Opportunities
    • Increased R&D funding and focus on product innovation
    • Stategic alliances and partnerships for antifungal drugs
  • Market Challenges
    • Presence of counterfeit drugs and patent expiration of branded drugs

Porter's Five Forces: A Strategic Tool for Navigating the Antifungal Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antifungal Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antifungal Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antifungal Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antifungal Drugs Market

A detailed market share analysis in the Antifungal Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antifungal Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antifungal Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antifungal Drugs Market

A strategic analysis of the Antifungal Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antifungal Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astellas Pharma Inc., Bayer HealthCare Pharmaceuticals LLC, Becton, Dickinson and Company, bioMerieux SA, Cadila Pharmaceuticals Limited, Cardinal Health, Inc., Cipla, Inc., Enzon Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Hologic, Inc., Johnson & Johnson, Lakewood-Amedex, Inc., Merck KGaA, Novartis AG, Pfizer, Inc., Quest Diagnostics Incorporated, SCYNEXIS, Inc., Sigma-Aldrich, Inc., and Sun Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Antifungal Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Infection Type, market is studied across Superficial Fungal Infection and Systemic Fungal infection.
  • Based on Type, market is studied across Allylamines, Azoles, Echinocandins, and Polyenes. The Allylamines is further studied across Butenafine, Naftifine, and Terbinafine. The Azoles is further studied across Imidazoles, Thiazoles, and Voricanazole. The Echinocandins is further studied across Anidulafungin, Caspofungin, and Micafungin. The Polyenes is further studied across Amphotericin B, Candicidin, Hamycin, and Natamycin.
  • Based on Form, market is studied across Ointments, Powder, and Tablets.
  • Based on Therapeutic Indications, market is studied across Aspergillosis, Candidiasis, and Dermatophytosis.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of fungal infection among population worldwide
      • 5.1.1.2. High awareness levels pertaining to myriad fungal infections
      • 5.1.1.3. Favorable government approvals for antifungal drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Continued preference for conventional antifungal drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increased R&D funding and focus on product innovation
      • 5.1.3.2. Stategic alliances and partnerships for antifungal drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Presence of counterfeit drugs and patent expiration of branded drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antifungal Drugs Market, by Infection Type

  • 6.1. Introduction
  • 6.2. Superficial Fungal Infection
  • 6.3. Systemic Fungal infection

7. Antifungal Drugs Market, by Type

  • 7.1. Introduction
  • 7.2. Allylamines
    • 7.2.1. Butenafine
    • 7.2.2. Naftifine
    • 7.2.3. Terbinafine
  • 7.3. Azoles
    • 7.3.1. Imidazoles
    • 7.3.2. Thiazoles
    • 7.3.3. Voricanazole
  • 7.4. Echinocandins
    • 7.4.1. Anidulafungin
    • 7.4.2. Caspofungin
    • 7.4.3. Micafungin
  • 7.5. Polyenes
    • 7.5.1. Amphotericin B
    • 7.5.2. Candicidin
    • 7.5.3. Hamycin
    • 7.5.4. Natamycin

8. Antifungal Drugs Market, by Form

  • 8.1. Introduction
  • 8.2. Ointments
  • 8.3. Powder
  • 8.4. Tablets

9. Antifungal Drugs Market, by Therapeutic Indications

  • 9.1. Introduction
  • 9.2. Aspergillosis
  • 9.3. Candidiasis
  • 9.4. Dermatophytosis

10. Americas Antifungal Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Antifungal Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Antifungal Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Astellas Pharma Inc.
  • 3. Bayer HealthCare Pharmaceuticals LLC
  • 4. Becton, Dickinson and Company
  • 5. bioMerieux SA
  • 6. Cadila Pharmaceuticals Limited
  • 7. Cardinal Health, Inc.
  • 8. Cipla, Inc.
  • 9. Enzon Pharmaceuticals, Inc.
  • 10. F. Hoffmann-La Roche Ltd.
  • 11. Gilead Sciences, Inc.
  • 12. Hologic, Inc.
  • 13. Johnson & Johnson
  • 14. Lakewood-Amedex, Inc.
  • 15. Merck KGaA
  • 16. Novartis AG
  • 17. Pfizer, Inc.
  • 18. Quest Diagnostics Incorporated
  • 19. SCYNEXIS, Inc.
  • 20. Sigma-Aldrich, Inc.
  • 21. Sun Pharmaceutical Industries Ltd.